Pharmaceuticals, Biotechnology and Life Sciences
Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.
Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.
Myriad Genetics, AstraZeneca, and Merck have expanded their companion diagnostic collaboration, to use BRACAnalysis CDx to identify germline BRCA mutations in…
Myriad Genetics’ study results on development of the adjusted Vectra, announced Wednesday, found it outperforming typical measures of disease activity in predicting new joint damage in rheumatoid arthritis patients.